Skip to main content
Premium Trial:

Request an Annual Quote

Itching to Sell

The New York Times has a piece up today on biotech companies that are contending with a sluggish market for psoriasis drugs. Despite having biologics that work, firms like Amgen, Genentech, and Biogen Idec have faced drooping sales for their respective psoriasis drugs. The article reports that the low sales can be traced to price barriers, as well as reluctance on the parts of doctors and insurers to prescribe and cover the treatments. This might be an early lesson for firms hoping to get genomics-based drugs on the market in coming years. We’re looking at you, RNAi.

 

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.